MedTrace Logo

Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure

NCT00030225 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2012-07-26

No results posted yet for this study

Summary

The purpose of this study is to determine if treatment with the ELAD Bioartificial Liver Assist Device is beneficial to patients in Acute Liver Failure either as a bridge to liver transplant or bridge to native liver recovery.

Conditions

  • Fulminant Hepatic Failure

Interventions

BIOLOGICAL

ELAD

OTHER

Standard of care (Control)

Sponsors & Collaborators

  • Vital Therapies, Inc.

    lead INDUSTRY

Principal Investigators

  • Patrick J Maguire, MD, PhD · VitaGen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2003-02-28
Completion
2003-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00030225 on ClinicalTrials.gov